NASDAQ:ADRO - Aduro BioTech Stock Price, Forecast & News

Aduro BioTech trades on the NASDAQ under the ticker symbol "ADRO."

Aduro BioTech Inc (NASDAQ:ADRO) announced its quarterly earnings results on Thursday, November, 7th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.03. The biotechnology company had revenue of $4.80 million for the quarter, compared to analysts' expectations of $4.55 million. Aduro BioTech had a negative net margin of 544.94% and a negative return on equity of 78.64%. View Aduro BioTech's Earnings History.

7 Wall Street analysts have issued 1 year price targets for Aduro BioTech's shares. Their forecasts range from $4.00 to $7.00. On average, they anticipate Aduro BioTech's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price. View Analyst Price Targets for Aduro BioTech.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aduro BioTech in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Aduro BioTech.

Media coverage about ADRO stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aduro BioTech earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View News Stories for Aduro BioTech.

Aduro BioTech saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 2,440,000 shares, an increase of 24.5% from the January 30th total of 1,960,000 shares. Based on an average daily trading volume, of 1,200,000 shares, the days-to-cover ratio is currently 2.0 days. Currently, 4.8% of the shares of the stock are short sold. View Aduro BioTech's Current Options Chain.

Some companies that are related to Aduro BioTech include Akebia Therapeutics (AKBA), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Supernus Pharmaceuticals (SUPN), NextCure (NXTC), Dermira (DERM), Enanta Pharmaceuticals (ENTA), I-Mab (ARQT), Odonate Therapeutics (ODT), Kiniksa Pharmaceuticals (KNSA), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Opko Health (OPK), Achillion Pharmaceuticals (ACHN) and Myovant Sciences (MYOV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aduro BioTech investors own include Regulus Therapeutics (RGLS), EXACT Sciences (EXAS), Flexion Therapeutics (FLXN), Paratek Pharmaceuticals (PRTK), Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), PTC Therapeutics (PTCT), Anavex Life Sciences (AVXL), MDxHealth (MXDHF) and Juno Therapeutics (JUNO).

(ADRO) raised $119 million in an IPO on Wednesday, April 15th 2015. The company issued 7,000,000 shares at a price of $17.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Aduro BioTech's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (5.76%), Baillie Gifford & Co. (5.26%), Ikarian Capital LLC (2.28%), State Street Corp (1.49%), Geode Capital Management LLC (1.08%) and Goldman Sachs Group Inc. (0.96%). Company insiders that own Aduro BioTech stock include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew, Natalie Sacks and Stephen T Isaacs. View Institutional Ownership Trends for Aduro BioTech.

ADRO stock was sold by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., State Street Corp, Assenagon Asset Management S.A. and Bank of America Corp DE. Company insiders that have sold Aduro BioTech company stock in the last year include Blaine Templeman, Celeste Ferber, Elsas Andrea Van, Jennifer Lew and Stephen T Isaacs. View Insider Buying and Selling for Aduro BioTech.

ADRO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Ikarian Capital LLC, Goldman Sachs Group Inc., Acadian Asset Management LLC, Jacobs Levy Equity Management Inc., J. Goldman & Co LP, Oxford Asset Management LLP and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Aduro BioTech.

Shares of ADRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADRO stock can currently be purchased for approximately $2.95.

Aduro BioTech has a market capitalization of $237.52 million and generates $15.09 million in revenue each year. The biotechnology company earns $-95,360,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Aduro BioTech employs 152 workers across the globe.View Additional Information About Aduro BioTech.

The official website for Aduro BioTech is http://www.aduro.com/.

Aduro BioTech's mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The biotechnology company can be reached via phone at 510-848-4400 or via email at [email protected]